Karen Moore 734-647-9956
Dr. Cuneo performs basic science, translational, and clinical research at the University of Michigan. His research focuses on the development of novel therapeutic approaches and biomarker discovery in gastrointestinal cancers. He serves as the principal investigator on clinical trials in pancreatic cancer, hepatocellular carcinoma, and colorectal cancer.
Areas of Interest
- Radiation sensitizers
- Adaptive radiation therapy
- Pancreatic cancer
- Hepatobiliary cancer
- Colorectal cancer
Honors & Awards
2016 Teacher of the Year, Radiation Biology
2015 GI SPORE Career Development Award
2006 AACR Scholar-In-Training Award
1995 Eagle Scout
- MD, Vanderbilt University Medical School, 2007
- Residency, Duke University Medical School, 2012
- BS, Cornell University
- Board Certification: Radiation Oncology
- NIH-DHHS-US-16 (PI: Dewaraja), 09/2016-06/2017, National Institutes of Health: Imaging and dosimetry of yttrium-90 for personalized cancer treatment, Role: Co-Investigator with Effort.
- (PI: Cuneo), 01/2016-01/2017, University of Michigan, Clinical / Translational Resource Allocation Committee: A study of circulating tumor cells and exosomes in patients treated with chemoradiation for adenocarcinoma of the pancreas, Role: Principal Investigator.
- (PI: Lubman), 04/2015-04/2017, National Institutes of Health:Therapeutic monitoring in pancreatic cancer Using an exosome based mass spec assay, Role: Co-Investigator with Effort.
- (PI: Cuneo/Morgan), University of Michigan Rogel Cancer Center: Therapeutic targeting of DNA repair for FBXW7 mutant colorectal cancers, Role: Co-Principal Investigator.
Selected from 24 publications
- An M, Lohse I, Tan Z, Zhu J, Wu J, Kurapati H, Morgan MA, Lawrence TS, Cuneo KC (co-senior author), Lubman DM. Quantitative proteomic analysis of serum exosomes from patients with locally advanced pancreatic cancer undergoing chemoradiotherapy. J Proteome Res. 16(4):1763-1772, 2017.
- Cuneo KC, Morgan MA, Davis MA, Parcels LA, Parsels J, Karnak D, Ryan C, Liu N, Maybaum J, Lawrence TS. Wee1 Kinase inhibitor AZD1775 radiosensitizes hepatocellular carcinoma regardless of TP53 mutational status through induction of replication stress. Int J Radiat Oncol Biol Phys. 95(2):782-90, 2016.
- Cuneo KC, Nyati MK, Ray D, Lawrence TS. EGFR targeted therapies and radiation: Optimizing efficacy by appropriate drug scheduling and patient selection. Pharmacol Ther.. 154:67-77, 2015.
- Cuneo KC, Davis MA, Feng MU, Novelli PM, Ensminger WD, Lawrence TS. Low dose rate radiosensitization of hepatocellular carcinoma in vitro and in patients. Translational Oncology. 7(4):472-8, 2014.
- Cuneo KC, Chenevert TL, Ben-Josef E, Feng MU, Greenson JK, Hussain HK, Simeone DM, Schipper MJ, Anderson MA, Zalupski MM, Al-Hawary M, Galban CJ, Rehemtulla A, Feng FY, Lawrence TS, Ross BD. A pilot study of diffusion-weighted MRI in patients undergoing neoadjuvant chemoradiation for pancreatic cancer. Translational Oncology. 7(5):644-9, 2014.